Kymera Therapeutics Inc (KYMR)

01:11 AM

Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance

01:11 AM

12:29 PM

Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating - MarketScreener

12:29 PM

08:19 AM

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network

08:19 AM

07:49 AM

Kymera Therapeutics Begins Dosing Patients in Phase 2 Trial of Potential Dermatitis Treatment - MarketScreener

07:49 AM

07:45 AM

Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial - GuruFocus

07:45 AM

07:23 AM

Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis - Investing.com Australia

07:23 AM

07:19 AM

Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis By Investing.com - Investing.com South Africa

07:19 AM

07:12 AM

Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma - Quiver Quantitative

07:12 AM

07:00 AM

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewswire Inc.

07:00 AM

Nov 24, 2025

Kymera Therapeutics stock hits 52-week high at 68.65 USD By Investing.com - Investing.com Nigeria

Nov 24, 2025

Nov 24, 2025

Kymera Therapeutics stock hits 52-week high at 68.65 USD - Investing.com India

Nov 24, 2025

Nov 24, 2025

Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 24, 2025

Nov 24, 2025

Kymera Therapeutics to Participate in Upcoming December Investor Conferences - The Manila Times

Nov 24, 2025

Nov 24, 2025

SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 24, 2025

Nov 24, 2025

Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan

Nov 24, 2025

Nov 23, 2025

Neo Ivy Capital Management Purchases 6,079 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 23, 2025

Nov 21, 2025

Will Kymera Therapeutics Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com

Nov 21, 2025

Nov 19, 2025

Kymera at Jefferies Conference: Targeted Protein Degradation Focus - Investing.com India

Nov 19, 2025

Nov 19, 2025

Kymera at Jefferies Conference: Targeted Protein Degradation Focus By Investing.com - Investing.com Canada

Nov 19, 2025

Nov 19, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 19, 2025

Nov 18, 2025

Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Update & Technical Buy Zone Confirmation - newser.com

Nov 18, 2025

Nov 18, 2025

Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week HighStill a Buy? - MarketBeat

Nov 18, 2025

Nov 18, 2025

Behavioral Patterns of KYMR and Institutional Flows - news.stocktradersdaily.com

Nov 18, 2025

Nov 16, 2025

Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Nov 16, 2025

Nov 16, 2025

How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Highlights & Expert Approved Momentum Ideas - newser.com

Nov 16, 2025

Nov 14, 2025

Stifel reiterates Buy rating on Kymera Therapeutics stock ahead of December data - Investing.com Canada

Nov 14, 2025

Nov 14, 2025

Is Kymera Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com

Nov 14, 2025

Nov 14, 2025

Why Kymera Therapeutics Inc. stock could outperform in 2025Trade Risk Summary & Weekly Top Performers Watchlists - Fundação Cultural do Pará

Nov 14, 2025

Nov 14, 2025

How to read the order book for Kymera Therapeutics Inc.Bear Alert & Low Risk High Reward Trade Ideas - newser.com

Nov 14, 2025

Nov 13, 2025

Kymera at TD Cowen Summit: Strategic Moves in Immunology By Investing.com - Investing.com Canada

Nov 13, 2025

Nov 13, 2025

What analysts say about Kymera Therapeutics Inc stockMoving Average Crossovers & Subscribe for Free Weekly Winners - earlytimes.in

Nov 13, 2025

Nov 13, 2025

What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com

Nov 13, 2025

Nov 12, 2025

What drives Kymera Therapeutics Inc stock priceStock Liquidity Analysis & Free Rapid Growing Investment Returns - earlytimes.in

Nov 12, 2025

Nov 12, 2025

Kymera Therapeutics stock hits 52-week high at 64.0 USD By Investing.com - Investing.com Philippines

Nov 12, 2025

Nov 11, 2025

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN

Nov 11, 2025

Nov 11, 2025

Kymera at Stifel Conference: Strategic Insights on Drug Development By Investing.com - Investing.com UK

Nov 11, 2025

Nov 11, 2025

Kymera Therapeutics stock hits 52-week high at 64.0 USD - Investing.com

Nov 11, 2025

Nov 11, 2025

Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN

Nov 11, 2025

Nov 11, 2025

Pattern recognition hints at Kymera Therapeutics Inc. upsideAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com

Nov 11, 2025

Nov 10, 2025

Transcript : Kymera Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 11 - MarketScreener

Nov 10, 2025

Nov 08, 2025

What is HC Wainwright's Forecast for KYMR FY2025 Earnings? - MarketBeat

Nov 08, 2025

Nov 08, 2025

Equities Analysts Set Expectations for KYMR FY2025 Earnings - MarketBeat

Nov 08, 2025

Nov 08, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at Wall Street Zen - MarketBeat

Nov 08, 2025

Nov 07, 2025

Kymera Therapeutics (KYMR) Gets a Buy from RBC Capital - The Globe and Mail

Nov 07, 2025

Nov 06, 2025

Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - MSN

Nov 06, 2025

Nov 06, 2025

Wells Fargo & Company Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat

Nov 06, 2025

Nov 06, 2025

Kymera Therapeutics Reports Q3 2025 Financial Results - MSN

Nov 06, 2025

Nov 06, 2025

Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail

Nov 06, 2025

Nov 06, 2025

HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN

Nov 06, 2025

Nov 06, 2025

Kymera upped to overweight by Wells Fargo on upcoming data - MSN

Nov 06, 2025